The PSI 2021 Conference will be run online between 21 to 23 June 2021.
Regarded as the principal annual event for statisticians in the pharmaceutical industry, the 2021 PSI Conference will be taking place online. The conference will be held over a three day period and will include plenary sessions, parallel sessions and
a poster display. Material will be also be available on demand plus there will be a virtual exhibitor area.
The PSI Scientific Committee have worked hard creating an exciting and relevant program. We are also incorporating interactive and sociable elements to try to recreate those aspects we know people love about the PSI Conference.
The conference agenda can be found here.
Registration is open!
We hope to ‘see’ many of you there.
Paul Terrill
PSI Conference Chair
Conference
Chair:
Paul Terrill
(PT Stat Consulting Ltd)
Conference
Vice Chair:
David Lawrence
(Novartis)
Committee
Chair:
Rachael Lawrence
(Adelphi Values)
Amitava Mukhopadhyay
(IQVIA)
Jennifer Gilbride
(GlaxoSmithKline)
Julia Niewczas
(AstraZeneca)
Julia Saperia
(MHRA)
Kristina Weber
(Roche)
Lynsey Womersley
(Veramed)
Maria Efstathiou
(IQVIA)
Martin Jenkins
(AstraZeneca)
Rosie Leach
(IQVIA)
Russell Jones
(Orchard Therapeutics)
After completing his PhD in statistics Paul started his career working as a statistician in the agrochemical industry at Jealott’s Hill, Berkshire before becoming a statistical trainer for SAS. He moved into the pharmaceutical industry in 2005 and primarily provides support to biotech and small pharmaceutical companies who lack in-house statistical expertise. Paul has been on the PSI Scientific Committee since 2014 and became the Scientific Committee Chair and a PSI Board Member in October 2017. In 2020 Paul took on the role of the Chair for the annual PSI conference. Outside of work Paul enjoys running and archery.
Since completing my PhD in epidemiology at the University of Edinburgh, UK, in 1999 I have worked as a clinical trial statistician on oncology and respiratory trials in both academia and the pharmaceutical industry. I currently work for Novartis in Switzerland leading the global statistical team on a large phase III program in asthma..
Rachael is Director and a Principal Statistician at Adelphi Values Patient Centered outcomes team, focused on the analysis and interpretation of PRO data in clinical trials. Previously Rachael has worked as a freelance consultant statistician and prior to that worked at AstraZeneca for sixteen years, including as a clinical trial statistician on phase III-IV oncology projects. Rachael has been a member of the PSI Scientific Committee since 2016, and a PSI Board Member and chair of Scientific Committee since June 2019. Outside of work she enjoys time with her family (husband and two sons) and loves fell running.
Amitava is an Associate Director, BioStatistics at Cytel since 2015. He has more than fifteen years of experience in the pharmaceutical industry with all phases of drug development in different therapeutic areas including oncology and ophthalmology. He was in academia for over a decade. His main focused areas are statistical methods in pharmacovigilance and spatio-temporal disease dynamics for personalized medicine. He has been engaged in PSI Scientific Committee since 2018.
Jennifer is a Statistics Leader at GSK in Stevenage, and has been at GSK since 2016. Jennifer has worked in Biometrics for around 25 years. During her career she has worked mainly in late phase and in several therapeutic areas; most recently Lupus, Rheumatoid Arthritis and Pain. Jennifer completed her first degree in Mathematics and Economics at the University of Durham, followed by an MSc in Applied Statistics from Sheffield Hallam University.
Jennifer joined the Scientific Committee in 2014 and has enjoyed working with the team on conferences, one day events and webinars.
Outside of work Jennifer enjoys walking, travel, good food and time with family and friends.
Julia is a clinical trial design methodology expert in the Biopharmaceuticals Statistical Innovation team at AstraZeneca. She consults teams on complex trial designs in Phase 2 and 3. Her areas of expertise include adaptive designs, group sequential designs and multiplicity. Recently, she developed interest in Bayesian designs. She received her BSc and MSc at Lancaster University in the UK and holds a PhD in Biostatistics from Medical University of Vienna.
Julia joined the PSI Scientific Committee in June 2020.
Julia is a statistical assessor at the Medicines and Healthcare products Regulatory Agency, where she has been working since 2012. She works across therapeutic areas and enjoys the variety and challenges. She completed her MSc in Statistics with Applications in Medicine from the University of Southampton in 2003 and between then and starting at the MHRA she has worked as a statistician and systematic reviewer in academia and in the public sector. She joined the PSI scientific committee in 2016. In her spare time -- oh, wait, what is that again? -- she sings (quite well) and plays the violin (very badly).
Kristina is a Senior Statistical Scientist at Roche, where she works primarily on late phase Neuroscience studies since 2018. She has previously worked as a statistician at the Medical School Hannover, Germany, where she worked on clinical trials across different indications and development phases. Kristina holds a PhD from the Medical School Hannover and holds a BSc and MSc in Mathematics. She has joined the PSI Scientific Committee beginning of 2020.
Lynsey works for Veramed as a Consultant Statistician with over 15 years industry experience. Lynsey has worked from across several phases including pre-clinical development, early phase and submission support including extensive Oncology experience.
Lynsey has been involved in the PSI Scientific committee since 2016.
Outside of work, Lynsey enjoys having fun with her family (husband and 2 daughters) and friends, camping and walking, plus teaching swimming at a local swimming club.
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book.
It has survived not only five centuries, but also the leap into electronic typesetting, remaining essentially unchanged. It was popularised in the 1960s with the release of Letraset sheets containing Lorem Ipsum passages, and more recently with desktop publishing software like Aldus PageMaker including versions of Lorem Ipsum.
Martin Jenkins is a Biometrics Team Leader at AstraZeneca in Cambridge. He is the statistical lead for several late stage product teams in the respiratory therapy area, and also has experience in rheumatology, dermatology and inflammatory diseases. Martin initially joined AstraZeneca in 2006, providing statistical support to translational science before moving into later phase clinical trials. He has been a member of the PSI scientific committee since 2017 and prior to that chaired the PSI Biomarker Special Interest Group for 6 years. He has published or presented in the fields of adaptive phase II/III seamless designs, biomarkers and estimands. Martin holds a undergraduate degree and masters in Mathematics from Cambridge University.
Rosie obtained an undergraduate degree in Mathematics in 2014 and then completed her MSc in Medical Statistics in 2016. Since then, she has worked as a statistician at Numerus UK and IQVIA. Rosie joined the Scientific Committee in October 2018. Outside of work, Rosie enjoys playing the drums.
Russell is a Director, Biostatistics at Orchard Therapeutics. After an honours degree in Mathematics he spent a few years teaching secondary mathematics with varying outcomes. The result of which led to him undertaking an MSc in Statistics at Southampton in 2006. Since then he has worked in varied areas of Clinical Biostatistics with particular interest in missing data topics. He has been a member of the PSI Scientific Committee since 2011.
Sarah is a Senior Statistical Scientist at Roche, where she has worked for the past 17 years. She has previously worked in the following therapeutic areas: inflammation, oncology and currently works in infectious diseases.
Sarah joined the Scientific Committee in October 2017 and is enjoying getting to know the committee members and helping to organise events.
Outside of work Sarah enjoys running, yoga and days out with her family.
Sue is Professor of Medical Statistics within the Department of Mathematics and Statistics at the University of Reading and has over 25 years’ experience as an applied academic statistician working in the fields of clinical trials and epidemiology. Her particular research areas of interest are adaptive designs and sequential clinical trials. Recent research has considered methodology for novel study design and analysis in these areas, in particular multi-arm multi-stage clinical trials involving treatment selection and multiple endpoints of interest.
Tobias is a statistical methodologist at Novartis in Basel, Switzerland, and works primarily on late phase studies. Previously, Tobias worked as a CMC statistician in the development of vaccines and biologicals. His current research interests are adaptive clinical trial designs, recurrent event modelling, estimands, and more recently missing data methodology. He received his PhD in the area of biostatistics from the University of Göttingen, Germany, and holds a BSc and a MSc in mathematics. Tobias joined the PSI Scientific Committee in January 2019.
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book.
It has survived not only five centuries, but also the leap into electronic typesetting, remaining essentially unchanged. It was popularised in the 1960s with the release of Letraset sheets containing Lorem Ipsum passages, and more recently with desktop publishing software like Aldus PageMaker including versions of Lorem Ipsum.
Our monthly webinar explores examples of innovative data visualisations relevant to our day to day work. Each month a new dataset is provided from a clinical trial or other relevant example, and participants are invited to submit a graphic that communicates interesting and relevant characteristics of the data.
R is quickly gaining popularity within the pharmaceutical industry due to it being a very powerful object-orientated language, and is able to produce analyses and high quality graphics. This will be a hands-on interactive course and will utilise the RStudio Cloud development environment.
In this talk we'll introduce the Grammar of Graphics, which allows you to compose graphs by combining independent components, and the implementation of this theory in R -- the ggplot2 package.
The format of this event will include Ted Talks by all of our speakers with the opportunity for us to have a discussion together after each of the presentations.
A year on after the final ICH E9 estimands addendum was published, we bring estimands to life. Members of the Estimands in Oncology special interest group will describe how the estimand framework provides a common language to describe the diversity of patient journeys and why it is important to address the right question in clinical trials.
This course will cover the essentials of DMC set up (roles and responsibilities, DMC charter, practical considerations), as well as discussing DMC case studies and the role of DMCs in adaptive trials and during the pandemic. In addition, there will be an interactive DMC workshop.
As a Director of Statistics, you will be accountable for guiding statisticians in their work, performing senior review of documentation and output deliveries, providing oversight and advising on best practices approach to statistics for clinical trials.
We're looking for an ambitious statistician with the technical and leadership skills to head up our growing consultancy business.
